Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ABT-239是一种新型、高效、非咪唑类H3R 拮抗剂,也是一种TRPV1拮抗剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 413 | 现货 | ||
5 mg | ¥ 926 | 现货 | ||
10 mg | ¥ 1,720 | 现货 | ||
25 mg | ¥ 3,710 | 现货 | ||
50 mg | ¥ 5,330 | 现货 | ||
100 mg | ¥ 7,530 | 现货 | ||
500 mg | ¥ 14,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 995 | 现货 |
产品描述 | ABT-239 is a novel, highly efficacious antagonist belonging to the non-imidazole class of histamine H3 receptor (H3R) antagonists. It also acts as a transient receptor potential vanilloid type 1 (TRPV1) antagonist. |
体外活性 | TMN perfusion with ABT-239 activates c-Fos selectively in the NBM and cortex[4]. Perfusion of the TMN with ABT-239 (10 μM) increases histamine release from the TMN, NBM, and cortex, but not from the striatum or NAcc. |
体内活性 | ABT-239 (3 mg/kg, i.p.) significantly delays onset of seizure, reduces behavioral seizures elicited by KA, and reduces in the incidence of head bobbing and forelimb clonus in mice. ABT-239 (3 mg/kg, i.p.) administration transforms a short-term learning event into a long-term remembered experience in WT but not in histamine-depleted mice[2]. ABT-239 (3 mg/kg, i.p.) causes enhanced reduction in all the stages. ABT-239 (3 mg/kg, i.p.) and TDZD-8 (10 mg/kg, i.p.) have more powerful reduction in the number of pyknotic neurons in mice hippocampi. ABT-239 (1 mg/kg, i.p.) in conbination with sub-therapeutic dose of SVP (150 mg/kg, i.p.), significantly decreases the number of immobility, head bobbing and forelimb clonus, where as a higher dose combination of The high dose combination of ABT-239 and TDZD-8 produces the most pronounced increase in Bcl-2 expression as well as decrease in the level of Bax[1]. Concomitant administration of either ABT-239 (1 and 3 mg/kg, i.p.) and nicotine (0.035 mg/kg, i.p.), or ABT-239 (0.1 mg/kg, i.p.) and nicotine (0.0175 mg/kg, i.p.) further increases nicotine-induced improvement in both memory acquisition and consolidation[3]. |
分子量 | 330.42 |
分子式 | C22H22N2O |
CAS No. | 460746-46-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90.0 mg/mL (272.4 mM)
H2O: insoluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.0265 mL | 15.1323 mL | 30.2645 mL | 75.6613 mL |
5 mM | 0.6053 mL | 3.0265 mL | 6.0529 mL | 15.1323 mL | |
10 mM | 0.3026 mL | 1.5132 mL | 3.0265 mL | 7.5661 mL | |
20 mM | 0.1513 mL | 0.7566 mL | 1.5132 mL | 3.7831 mL | |
50 mM | 0.0605 mL | 0.3026 mL | 0.6053 mL | 1.5132 mL | |
100 mM | 0.0303 mL | 0.1513 mL | 0.3026 mL | 0.7566 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ABT-239 460746-46-7 Membrane transporter/Ion channel TRP/TRPV Channel ABT 239 ABT239 Inhibitor inhibitor inhibit